about
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.Internal tandem duplications of the FLT3 gene are present in leukemia stem cellsThe clinical development of FLT3 inhibitors in acute myeloid leukemia.Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT.
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Novel FLT3 tyrosine kinase inhibitors.
@ast
Novel FLT3 tyrosine kinase inhibitors.
@en
type
label
Novel FLT3 tyrosine kinase inhibitors.
@ast
Novel FLT3 tyrosine kinase inhibitors.
@en
prefLabel
Novel FLT3 tyrosine kinase inhibitors.
@ast
Novel FLT3 tyrosine kinase inhibitors.
@en
P2860
P1476
Novel FLT3 tyrosine kinase inhibitors.
@en
P2093
Donald Small
Mark Levis
P2860
P304
P356
10.1517/13543784.12.12.1951
P407
P577
2003-12-01T00:00:00Z